Last $5.82 USD
Change Today +0.06 / 1.04%
Volume 143.5K
NBS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 08/26/14 All times are local (Market data is delayed by at least 15 minutes).

neostem inc (NBS) Snapshot

Open
$5.74
Previous Close
$5.76
Day High
$5.84
Day Low
$5.74
52 Week High
09/13/13 - $9.89
52 Week Low
05/9/14 - $4.56
Market Cap
205.2M
Average Volume 10 Days
153.4K
EPS TTM
$-1.81
Shares Outstanding
35.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEOSTEM INC (NBS)

Related News

No related news articles were found.

neostem inc (NBS) Related Businessweek News

No Related Businessweek News Found

neostem inc (NBS) Details

NeoStem, Inc. develops cell based therapeutics. The company is involved in the manufacture of cell therapy-based products; and provides product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. It also offers contract development and manufacturing services to clients advancing in the regenerative medicine industry; and collects, processes, and stores umbilical cord blood units and adult stem cells. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. In addition, it develops T regulatory cell based therapeutics to treat diseases caused by imbalances in the immune system; and researches and develops therapeutics based on very small embryonic-like technology. The company has a collaboration agreement with Becton-Dickinson. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.

108 Employees
Last Reported Date: 03/13/14
Founded in 1980

neostem inc (NBS) Top Compensated Officers

Executive Chairman and Chief Executive Office...
Total Annual Compensation: $945.0K
Chief Financial Officer and Vice President
Total Annual Compensation: $190.6K
President of Progenitor Cell Therapy, LLC and...
Total Annual Compensation: $494.2K
Chief Visionary Officer, Director, Chief Scie...
Total Annual Compensation: $586.5K
Chief Medical Officer
Total Annual Compensation: $331.5K
Compensation as of Fiscal Year 2013.

neostem inc (NBS) Key Developments

Neostem, Inc. Presents at Swedish-American Life Science Summit 2014, Aug-22-2014 10:30 AM

Neostem, Inc. Presents at Swedish-American Life Science Summit 2014, Aug-22-2014 10:30 AM. Venue: EY Headquarters, Stockholm, Sweden. Speakers: Hans S. Keirstead, President of NeoStem Oncology.

NeoStem, Inc. Announces Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

NeoStem, Inc. announced earnings results for the second quarter and six months ended June 30, 2014. Total revenue for the three months ended June 30, 2014 was $4.5 million, up 3% from $4.4 million for the prior year period. Clinical services and reimbursable revenue, representing approximately 80% of total revenues, increased slightly compared with the prior year period. Net loss for the three months ended June 30, 2014 was $12.8 million compared with $8.6 million for the three months ended June 30, 2013. Net loss excluding non-cash charges for the six months ended June 30, 2014 was $26.6 million or $19.4 million compared with $13.1 million for the six months ended June 30, 2013 or $13.1 million when excluding non-cash charges. Net loss was $26.6 million against $17.5 million a year ago.

Neostem, Inc. Presents at Global Online CEO Conference, Jul-16-2014 12:30 PM

Neostem, Inc. Presents at Global Online CEO Conference, Jul-16-2014 12:30 PM.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NBS:US $5.82 USD +0.06

NBS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aastrom Biosciences Inc $3.89 USD -0.01
Biorestorative Therapies Inc $0.33 USD -0.005
BioTime Inc $2.95 USD +0.18
IntelliCell BioSciences Inc $0.0014 USD +0.0002
Organovo Holdings Inc $7.92 USD -0.02
View Industry Companies
 

Industry Analysis

NBS

Industry Average

Valuation NBS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.2x
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEOSTEM INC, please visit www.neostem.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.